Either formulation requires the same safety communication with your surgeon
Source: New England Journal of Medicine - STEP 1 Trial 20% lower risk of heart attack and stroke SELECT trial showed semaglutide reduces major cardiovascular events (death, heart attack, stroke) by 20% in people with obesity
Be wary of products marketed as 'research chemicals' that are clearly intended for human use
Endocrinology 160 , 19501963 (2019)
The double-blind, parallel-group, randomized and placebo-controlled 68-week clinical trial compared the effects of a subcutaneous 2.4 mg once-weekly semaglutide injection versus placebo in 201 adolescents with obesity
Karg E, Odh G, Wittbjer A, Rosengren E, Rorsman H